List view / Grid view
7 November 2014 | By Felicitex Therapeutics and Selvita
Felicitex Therapeutics and Selvita have announced that they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors...
7 November 2014 | By CARLINA Technologies
CARLINA Technologies announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein...
6 November 2014 | By Cardio3 BioSciences
Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery...
29 October 2014 | By Probiodrug AG
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
28 October 2014 | By TxCell
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease...
24 October 2014 | By The Institute of Cancer Research, London
Leading expert calls for major changes to restock pipeline with innovative cancer treatments...
22 October 2014 | By The European Infrastructure for Translational Medicine
EATRIS, TIA, NCATS and CDRD join forces to share knowledge and insight..
22 October 2014 | By Rosetta Genomics Ltd
Rosetta Genomics Ltd. announces the initiation by the European Infrastructure for Translational Medicine, of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic...
22 October 2014 | By Mucosis B.V.
Mucosis B.V. will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014...
21 October 2014 | By Calixar
Aston University (Birmingham - UK) and Calixar SAS (Lyon-France) have concluded a new research agreement through the “BBSRC Industrial CASE Studentship Competition 2013” framework...
15 October 2014 | By Seahorse Bioscience
Seahorse Bioscience and the University of Alabama at Birmingham announced that they have entered into a partnership to study the bioenergetic health of cells in cryo-preserved blood – a step that will ultimately produce a first-of-its-kind clinical test of metabolic bioenergetic health...
15 October 2014 | By Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
14 October 2014 | By Imaxio
Imaxio announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg...
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
